LegalJul 16, 2026, 07:36 AM
Arbutus receives $178M Moderna payment, plans $230M capital return
AI Summary
Arbutus Biopharma received approximately $178 million as its share of a noncontingent settlement payment from Moderna, resolving global patent infringement litigation. The company also announced plans to return up to $230 million in capital to shareholders through share repurchases, following an expected dividend from Genevant in Q3 2026. Additionally, Arbutus terminated an agreement with Genevant for a $1 million fee and initiated new international patent infringement lawsuits against Pfizer and BioNTech, while also filing a complaint against the U.S. Government related to Moderna's infringement.
Key Highlights
- Received approximately $178M from Moderna as noncontingent settlement payment.
- Potential for additional contingent payment of up to $1.3B from Moderna.
- Plans to return up to $230M in capital to shareholders via share repurchases.
- Initiated three new international patent infringement lawsuits against Pfizer/BioNTech.
- Filed complaint against the U.S. Government for Moderna's infringement.
- Terminated RSV Agreement with Genevant, receiving a $1.0M termination fee.
- CEO to receive 1.5% bonus on Moderna noncontingent payment, CFO 0.25%.
Price Impact
More from ABUS